x

OUR PASSION FOR PROGRESS™ BEGINS WITH OUR PIPELINE

For more than a decade, Neurelis has been working diligently to develop a pipeline of products and technologies to address significant unmet needs for patients.

NEURELIS PIPELINE

pipeline graphic
polygonPRE-CLIN
 
dotted circle

NRL-2

NRL-3

NRL-4

Phase 1PHASE
1
 
dotted circle

OPNT002

Phase 2PHASE
2
 
dotted circle

ARS-1

OPNT003

Phase 3PHASE
3
 
dotted circle

 

NDANDA
 
dotted circle

 

FDAFDA
APPROVED
 
dotted circle

VALTOCO®
(diazepam nasal spray)

TOSYMRA™
(sumatriptan nasal spray)

NEURELIS PROGRAMS

NEURELIS PROGRAMS
DESCRIPTION
USE
DISEASE STATE
STATUS
 
VALTOCO®
(diazepam nasal spray)
Diazepam Nasal Spray
Acute
Cluster Seizures (ARS)
polygonFDA Approved
Details
LEARN MORE ABOUT VALTOCO® >
 
Click here for full prescribing and important safety information.
NRL-2
Intranasal formulation with Intravail®
Acute
Anxiety
polygonPre-Clin
Details
LEARN MORE ABOUT NRL-2 >
NRL-3
Intranasal formulation with Intravail®
Acute
Epilepsy
polygonPre-Clin
Details
LEARN MORE ABOUT NRL-3 >
NRL-4
Intranasal formulation with Intravail®
Acute
Psychomotor Agitation
polygonPre-Clin
Details
LEARN MORE ABOUT NRL-4 >

Select Partner Programs

Select PARTNER PROGRAMS
DESCRIPTION
DISEASE STATE
STATUS
DETAILS
TOSYMRA™
(sumatriptan nasal spray)
Sumatriptan Nasal Spray
Acute Migraines
polygonFDA Approved
  • Upsher-Smith
  • Approved - Jan 2019
 
Tosymra is a trademark of Upsher-Smith Laboratories, LLC. Click here for full prescribing and important safety information.
ARS-1
Epinephrine Nasal Spray
Anaphylaxis
polygonPhase 2
  • ARS Pharmaceuticals
  • Fast Track designation
OPNT003
Nalmefene Nasal Spray
Opioid Overdose
polygonPhase 2
  • Opiant Pharmaceuticals
OPNT002
Opioid Antagonist Nasal Spray
Alcohol Use Disorder
polygonPhase 1
  • Opiant Pharmaceuticals

LEARN MORE ABOUT OUR INNOVATIVE PRODUCT AND PIPELINE PROGRAMS

VALTOCO
NRL-2
NRL-3
NRL-4

THE NEURELIS TEAM HAS A ROBUST HISTORY OF CNS INDUSTRY EXPERIENCE

SEE OUR TECHNOLOGIES
SEE OUR PARTNERS